We design and lead clinical trials with a goal to bring new treatments to stroke patients. Although the underlying science must be rigorous and sound, collaboration and communication are critical to translating that science into new treatments to patients. Work in our laboratory seeks to understand how a pharmacologic intervention is linked to the hypothesized mechanism of action in patients. Frequently, there are subtle but important differences between model organisms and patients that can have significant implications for optimal trial design. In this regard, biomarkers and intermediate endpoints can assist interpretation of early phase clinical trial results and inform subsequent development.
Below are some examples of our clinical trial projects.
